A Phase 3 TAISHAN-302 trial reported that Tam-Peli, an anti-B7-H3 antibody-drug conjugate, cut the risk of death by 54% versus topotecan in relapsed small-cell lung cancer. The study reinforces B7-H3 as a therapeutic target in a setting where second-line options have historically produced modest outcomes. The reported effect size adds weight to the ADC approach as a next-generation alternative to chemotherapy in platinum-pretreated disease. Clinically, the data strengthen the case for B7-H3-targeted ADC development and potential label expansion discussions, depending on confirmatory endpoints, safety findings, and regulatory review in the jurisdictions covering the trial program.